
Innovation in medicine **R&D** and access

Key

Mid-term ABPI/industry focus - UK level









1	£436 million	£533 million	£710 million	£916 million	£1.1 billion	£1.15 billion	
	5,000 - 10,000	77.					
	¦ candidates	10-20 candidates	5-10 candidates	2-5 candidates	i 1-2 candidates	1 medicine	
Pre discovery	Drug discovery	Pre-clinical testing	Phase 1 clinical trial	Phase 2 clinical trial	Phase 3 clinical trial	Licensing approval	Medicine available for patients

Based on their disease focus. companies' scientists work to understand the disease

Researchers select a 'target', such as a gene or protein, then search for a molecule, or compound, that may act on the 'target' to alter the disease

Early safety and

efficacy tests are undertaken in computational models, cells and in animals

The candidate medicine is tested in people for the first time. Studies are conducted with about 20 to 100

healthy volunteers

Researchers evaluate the candidate medicine's efficacy in about 100 to 500 patients with the disease

Researchers study the candidate medicine in about 1,000 to 5,000 patients to generate data about safety, efficacy and the overall benefit-risk

relationship of

the medicine

Information and results from all the studies is compiled and submitted to the regulatory agencies

The medicine is now licensed for use and patients may benefit from it, subject to value and cost-effectiveness assessments and local health budget availability